• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Future Directions and Overcoming Challenges in BTK Inhibitor Therapy

Opinion
Video

Panelists discuss challenges oncologists face in managing treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), including balancing efficacy with adverse effect profiles, and highlight strategies such as multidisciplinary collaboration and access to updated treatment guidelines to address these issues while also expressing eagerness for future advancements in Bruton tyrosine kinase (BTK) inhibitors and the need for further research to refine treatment strategies and improve patient outcomes.

  1. What are other challenges oncologists face when managing treatment-naive patients with CLL and MCL, and what strategies or resources can help overcome these challenges?
  2. What are you most eager to see regarding the future use of BTK inhibitors, and what areas of research or collaboration are needed to further improve patient outcomes?
Related Videos
3 experts are featured in this series.
1 expert is featured in this series.
3 experts are featured in this series.
1 expert is featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.